← Back to Clinical Trials
Recruiting NCT05799872

NCT05799872 Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05799872
Status Recruiting
Phase
Sponsor Virginia Commonwealth University
Condition Anorexia Nervosa
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2023-12-06
Primary Completion 2026-07-30

Trial Parameters

Condition Anorexia Nervosa
Sponsor Virginia Commonwealth University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 90
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-12-06
Completion 2026-07-30
Interventions
Positive Affect Treatment for Anorexia Nervosa (PAT-AN):Psychoeducational and Behavioral Therapy (PBT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The investigators will recruit individuals with broadly-defined AN (n = 80) who are currently in or have recently participated in higher-level eating disorder treatment (e.g., residential, partial hospitalization/day treatment, intensive outpatient treatment). Interested participants will sign consent, complete eligibility assessments, and will be randomized to receive Positive Affect Treatment for Anorexia Nervosa (PAT-AN) or Psychoeducation and Behavioral Therapy (PBT) through teletherapy shortly following discharge from higher level of care. Participants can participate in most other forms of outpatient treatment while receiving the research intervention. Participants will engage in 24 weeks of PAT-AN or PBT starting in the first 3 months post-discharge. At each session, the investigators will complete brief measures assessing treatment acceptability, affect, and eating disorder symptoms. Participants will also complete an assessment battery of self-report, EMA, and neurocognitive measures evaluating primary outcomes (BMI; eating disorder symptoms), secondary outcomes (depression, anxiety, and suicidality), and presumed treatment mechanisms at baseline, end of treatment (EOT), and 3-month follow-up (FU). All assessments will be remotely delivered via HIPAA-compliant platforms.

Eligibility Criteria

Inclusion Criteria: 1. Age \> or = 18 years old 2. Ability to read and speak in English 3. DSM-5 diagnosis of AN or atypical AN at admission to higher-level care 4. In higher-level care discharging to outpatient care or discharged to outpatient care within the past 3 months 5. Current BMI \> or = 18.5 kg/m2 (or will be by time of discharge) 6. BMI increase of \> or = 0.5 kg/m2 while in higher-level care 7. Ability to designate and sign a release of information for a primary physical or mental health provider for study duration 8. Willingness to participate in weekly assessments (e.g., weight monitoring) and audio or video recording of study therapy sessions for study duration 9. Access to a smartphone and/or computer permitting engagement in remote therapy and assessment. Exclusion Criteria: 1. Medical instability for outpatient care; 2. Pregnancy 3. Lifetime DSM-5 primary psychotic or bipolar-I disorder 4. Current DSM-5 substance use disorder 5. Enrollment in outpatient therapy with h

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology